TherapeuticsMD (TXMD) Tops Q3 EPS by 4c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.22 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Carnival shares drop despite earnings beat on weak guidance
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus